Merlin restoration prevents schwannoma progression in a genetically engineered mouse model of NF2-SWN
- 1Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angele
Abstract
Patients with NF2-related schwannomatosis (NF2-SWN) present with hallmark bilateral vestibular schwannomas, but also schwannomas on other cranial, spinal, and peripheral nerves, as well as meningiomas and ependymomas, caused by germline mutations in the tumor suppressor gene NF2. Current therapies involving surgery and radiosurgery are effective for individual tumors but are not always a viable option for patients with multiple tumors, and harbor significant risk of neurological deficits and morbidity. Gene replacement therapy is becoming a promising new treatment strategy for several neurologic diseases. This study aims to understand if restoration of a functional merlin protein, gene product of the Nf2 gene, in Nf2-deficient tumor cells, can provide preclinical therapeutic efficacy in a NF2-SWN genetically engineered mouse model. We have developed a new Nf2 allele (Nf2FRT) that allows to conditionally restore Nf2 expression by activation with the Flp recombinase. We generated a new mouse model using the Nf2FRT allele in combination with Nf2flox and Postn-Cre alleles. Using the new conditional schwannoma mouse model Postn-Cre;Nf2FRT/flox;R26FlpoER, we validated the hypothesis that restoration of Nf2 reduces the growth of schwannoma. Demonstrating that merlin restoration effectively controls schwannoma growth is a crucial first step toward developing this concept as a new therapeutic strategy for potentially treating schwannomas. The new mouse model will be used to better understand the cellular and molecular mechanisms involved in stopping the growth of Nf2-deficient tumors.
Related
- 556 A phase I first-in-human trial of IL-12 genetically engineered myeloid cells in participants with relapsed, refractory solid tumors
- Adolescent environmental enrichment prevents early-life stress-induced schizophrenia-like phenotypes via restoration of CREB-BDNF-TrkB signaling.
- Peptide-mediated inhibition of aberrant chaperone-mediated autophagy in pericytes prevents glioblastoma progression through MAPT/tau secretion
- Human trilayer engineered blood vessel reveals influence of fibroblasts on disease progression in model of Hutchinson-Gilford progeria
- Nerve-sparing resection of cervical vagal schwannoma with complete functional recovery: a case report
BibTeX
@misc{vitte2026merlin,
title = {{Merlin restoration prevents schwannoma progression in a genetically engineered mouse model of NF2-SWN}},
author = {J. Vitte and C. Chiasson-MacKenzie and B. K. Cole and A. I. McClatchey and M. Giovannini},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.12.751200},
url = {https://www.biorxiv.org/content/10.64898/2026.09.12.751200v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Merlin restoration prevents schwannoma progression in a genetically engineered mouse model of NF2-SWN
AU - J. Vitte
AU - C. Chiasson-MacKenzie
AU - B. K. Cole
AU - A. I. McClatchey
AU - M. Giovannini
PY - 2026
DA - 2026/09/12
PB - bioRxiv
DO - 10.64898/2026.09.12.751200
UR - https://www.biorxiv.org/content/10.64898/2026.09.12.751200v1
AB - Patients with NF2-related schwannomatosis (NF2-SWN) present with hallmark bilateral vestibular schwannomas, but also schwannomas on other cranial, spinal, and peripheral nerves, as well as meningiomas and ependymomas, caused by germline mutations in the tumor suppressor gene NF2. Current therapies involving surgery and radiosurgery are effective for individual tumors but are not always a viable option for patients with multiple tumors, and harbor significant risk of neurological deficits and morbidity. Gene replacement therapy is becoming a promising new treatment strategy for several neurologic diseases. This study aims to understand if restoration of a functional merlin protein, gene product of the Nf2 gene, in Nf2-deficient tumor cells, can provide preclinical therapeutic efficacy in a NF2-SWN genetically engineered mouse model. We have developed a new Nf2 allele (Nf2FRT) that allows to conditionally restore Nf2 expression by activation with the Flp recombinase. We generated a new mouse model using the Nf2FRT allele in combination with Nf2flox and Postn-Cre alleles. Using the new conditional schwannoma mouse model Postn-Cre;Nf2FRT/flox;R26FlpoER, we validated the hypothesis that restoration of Nf2 reduces the growth of schwannoma. Demonstrating that merlin restoration effectively controls schwannoma growth is a crucial first step toward developing this concept as a new therapeutic strategy for potentially treating schwannomas. The new mouse model will be used to better understand the cellular and molecular mechanisms involved in stopping the growth of Nf2-deficient tumors.
ER -